August 2026
M	T	W	T	F	S	S
	1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31

May 23, 2026, 16:38

José Octavio Alva Bucio: Securing the Future of Plasma and Blood-Derived Medicines

José Octavio Alva Bucio, Chief Operating Officer (COO) at Genbio, shared a post on LinkedIn:

“Latin America appears to be entering a new phase in the conversation surrounding blood donation, plasma, and plasma-derived medicinal products.

In recent weeks, important regulatory developments have taken place across the region, reflecting a significant shift: plasma and plasma-derived therapies are beginning to occupy an increasingly strategic position within healthcare systems.

For example, in Argentina, the exclusively voluntary blood donation model was recently reinforced through the formal elimination of replacement donation within the healthcare system. Meanwhile, in Mexico, regulatory and technical efforts related to the utilization and industrial processing of recovered plasma continue to advance — although still largely unnoticed by many observers.

These are distinct and seemingly unrelated approaches; however, both reflect a shared regional reality: Latin America is beginning to engage more deeply with, and make decisions about, issues that for many years remained largely outside the sphere of public debate and policy action:

Plasma availability
Blood donation models
Health sovereignty
Industrial processing capacity
Sustainable access to plasma-derived medicinal products

What is particularly noteworthy is that these developments are taking place within a global context in which demand for immunoglobulins, albumin, and other plasma-derived therapies continues to grow rapidly. This trend will inevitably push healthcare systems to confront a fundamental question — and the sooner this occurs, the better:

How can we build sustainable models capable of guaranteeing long-term access, safety, and sufficiency of blood components and plasma-derived medicines?

Beyond the differences in the maturity of regulatory agencies across the region, the central challenge for each country will be to develop frameworks capable of balancing:

Ethics
Sustainability
Industrial capacity
Patient access

For this reason, I believe that the progress we are witnessing across the region clearly demonstrates that these issues are finally beginning to be taken seriously.

I am convinced that the evolution of these discussions over the coming months will lead us toward a new level of engagement, collaboration, and network-building.

The conversation continues.”

José Octavio Alva Bucio: Securing the Future of Plasma and Blood-Derived Medicines